SAN DIEGO– Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that Dr. Klaus Wagner has been appointed as Chief Medical Officer.
“We are excited to have Klaus join at this pivotal time as we advance the first ecDNA therapeutics towards the clinic,” said Zachary Hornby, President and Chief Executive Officer of Boundless Bio. “Klaus brings extensive experience in oncology drug development from both industry and clinical research settings. Over the course of his career, he has developed a deep understanding of how cancer targeted therapies and immunotherapies perform in the clinic. His leadership over Boundless Bio’s clinical development will bring significant value to our ecDNA-directed therapeutic (ecDTx) programs and importantly, help us bring new treatment options to patients with oncogene amplified cancer.”
Dr. Wagner comes to Boundless Bio previously serving as Executive Vice President and Chief Medical Officer at Inhibrx, Inc. At Inhibrx, Dr. Wagner built and led an integrated clinical development organization responsible for advancing four therapeutic candidates, including three oncology programs, from pre-IND into the clinic. Dr. Wagner previously served as Medical Oncologist at Banner MD Anderson Cancer Center and as Adjunct Assistant Professor in the Department of Thoracic, Head & Neck Medical Oncology at MD Anderson Cancer Center, where he led molecularly targeted therapy and cancer immunotherapy trials in non-small cell lung cancer as a local principal investigator. Before that, Dr. Wagner trained at MD Anderson Cancer Center as a fellow in Medical Oncology. Prior to that Dr. Wagner’s scientific work at Genentech, Inc. and the Genomics Institute of the Novartis Research Foundation focused on cancer drug discovery and predictive biomarker development. Dr. Wagner was a scholar of the German National Academic Scholarship Foundation. Dr. Wagner received his M.D. and Ph.D. from the Friedrich-Alexander University of Erlangen in Germany.
“It is a privilege to join Boundless Bio, a company founded on interrogating a fundamental and important area of cancer biology, ecDNA that appears to play a significant role in the poor prognosis and treatment challenges associated with oncogene amplified cancers,” said Dr. Wagner. “In my career as a scientist and clinician, I have always been excited to bring innovative treatments to patients with high unmet needs cancer. There are very few therapies that effectively address oncogene amplification. Boundless Bio’s pipeline is uniquely tailored to develop treatments for these patients.”
